Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$86000.0.

  • Altimmune's Other Non Operating Income fell 57777.78% to -$86000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$45000.0, marking a year-over-year increase of 1000.0%. This contributed to the annual value of $48000.0 for FY2024, which is 7108.43% down from last year.
  • Altimmune's Other Non Operating Income amounted to -$86000.0 in Q3 2025, which was down 57777.78% from -$92000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Other Non Operating Income ranged from a high of $118000.0 in Q4 2024 and a low of -$286000.0 during Q3 2021
  • Moreover, its 5-year median value for Other Non Operating Income was $15000.0 (2025), whereas its average is -$18684.2.
  • The largest annual percentage gain for Altimmune's Other Non Operating Income in the last 5 years was 54232.73% (2021), contrasted with its biggest fall of 107884.87% (2021).
  • Over the past 5 years, Altimmune's Other Non Operating Income (Quarter) stood at -$81000.0 in 2021, then plummeted by 167.9% to -$217000.0 in 2022, then skyrocketed by 109.22% to $20000.0 in 2023, then skyrocketed by 490.0% to $118000.0 in 2024, then crashed by 172.88% to -$86000.0 in 2025.
  • Its Other Non Operating Income was -$86000.0 in Q3 2025, compared to -$92000.0 in Q2 2025 and $15000.0 in Q1 2025.